As a developed approach to treat cancer, the combined application of auranofin and the tyrosine kinase inhibitor lenvatinib enhances ROS accumulation, endoplasmic reticulum stress, and ROS-dependent JNK signaling and subsequently induces synergistic anti-cancer effects in human lung cancer cells, such as H1299, H520, and A549 cells [92]. The gene discussed is MAPK8; the disease is cancer.